Evidence map›Paper›PMID 41453592›Full record

ArticleAmerican journal of ophthalmology2026

Elevated Retinal Neovascularization on Widefield Optical Coherence Tomography Angiography Predicts Complications in High-Risk Proliferative Diabetic Retinopathy.

An-Lun Wu, Jinyi Hao, Liqin Gao, Yukun Guo, Tristan T Hormel, Christina J Flaxel, Merina Thomas, Benjamin K Young, Steven T Bailey, Dong-Wouk Park and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

An-Lun WuFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA; Department of Ophthalmology (A.L.W.), Mackay Memorial Hospital, Hsinchu, Taiwan.
Jinyi HaoFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA; Department of Biomedical Engineering (J.H., Y.G., Y.J.), Oregon Health & Science University, Portland, Oregon, USA.
Liqin GaoFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA.
Yukun GuoFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA; Department of Biomedical Engineering (J.H., Y.G., Y.J.), Oregon Health & Science University, Portland, Oregon, USA.
Tristan T HormelFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA.
Christina J FlaxelFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA.
Merina ThomasFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA.
Benjamin K YoungFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA.
Steven T BaileyFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA.
Dong-Wouk ParkFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA.
Yali JiaFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA; Department of Biomedical Engineering (J.H., Y.G., Y.J.), Oregon Health & Science University, Portland, Oregon, USA.
Thomas S HwangFrom the Casey Eye Institute (A.L.W., J.H., L.G., Y.G., T.T.H., C.J.F., M.T., B.K.Y., S.T.B., D.W.P., Y.J., T.S.H.), Oregon Health & Science University, Portland, Oregon, USA. Electronic address: hwangt@ohsu.edu.

Funding

Oregon Clinical and Translational Research InstituteUL1TR002369 · OREGON HEALTH & SCIENCE UNIVERSITY · 2025 to 2025
$9.9M
Proteomics CoreP30EY010572 · OREGON HEALTH & SCIENCE UNIVERSITY · 1995 to 2025
$4.4M
Advancing visible-light OCT in oxygen-induced retinopathyR01EY036429 · OREGON HEALTH & SCIENCE UNIVERSITY · 2025 to 2025
$692k
OCT Angiography for Age-related Macular DegenerationR01EY024544 · OREGON HEALTH & SCIENCE UNIVERSITY · 2025 to 2025
$680k
OCTA Precursors of Vision-Threatening Complications of Diabetic RetinopathyR01EY035410 · OREGON HEALTH & SCIENCE UNIVERSITY · 2025 to 2025
$627k
Translational Vision Science Research at Oregon Health & Science UniversityT32EY023211 · OREGON HEALTH & SCIENCE UNIVERSITY · 2025 to 2025
$178k
NCATS NIH HHS UL1 TR002369NEI NIH HHS P30 EY010572NEI NIH HHS R01 EY024544NEI NIH HHS R01 EY027833NEI NIH HHS R01 EY031394NEI NIH HHS R01 EY035410NEI NIH HHS R01 EY036429NEI NIH HHS R43 EY036781NEI NIH HHS T32 EY023211NIDDK NIH HHS DP3 DK104397
6 · The paper itself

Abstract

purposeTo determine whether retinal neovascularization (RNV) metrics derived from single-shot widefield swept-source OCT angiography (SS-OCTA) predict subsequent vision-threatening complications in eyes with high-risk proliferative diabetic retinopathy (PDR).

designProspective case series.

participantsEyes clinically graded as high-risk PDR at a tertiary care center, followed up for at least 6 months.

methodsEligible eyes underwent single-shot 26 × 21-mm SS-OCTA imaging (DREAM OCT, Intalight Inc.). A validated deep learning-based algorithm segmented the vitreous cavity slab to generate en face OCTA images for automated detection and quantification of RNV membrane and the vascular areas. Lesions were classified as elevated when they were separated from the internal limiting membrane (ILM) and attached when there was no space between the lesion and the ILM. We analyzed baseline OCTA-derived metrics for their predicting eyes that developed new or recurrent vitreous hemorrhage (VH) or tractional retinal detachment (TRD) during follow-up.

main outcome measuresIncidence of new or recurrent vitreous hemorrhage and traction retinal detachment.

resultsOver a median follow-up period of 291 days (range, 180-466), 8 of 18 eyes (44.4%) developed complications, with 7 (38.9%) developing VH and 1 (5.6%) developing TRD. Among the 115 identified RNV lesions, 87 (75.7%) were located outside the arcades. Compared to eyes without complications, eyes with complications had a larger median total RNV membrane area (25.72 mm² vs 1.33 mm²; P = .006) and a larger median total RNV vascular area (9.72 mm² vs 0.76 mm²; P = .010). Eyes with complications had a larger elevated RNV membrane area (5.13 mm

conclusionsWidefield SS-OCTA is useful for evaluating RNV burden and its axial relationship to the ILM in high-risk PDR. Elevated baseline RNV, incorporating spatial and anatomic features, predicts subsequent tractional complications such as VH and TRD. These imaging biomarkers may complement current clinical staging of PDR.

Indexed as

Diabetic RetinopathyFluorescein AngiographyRetinal DetachmentRetinal NeovascularizationTomography, Optical CoherenceVitreous HemorrhageAdultAgedFemaleFollow-Up StudiesFundus OculiHumansMaleMiddle AgedPredictive Value of TestsProspective Studies

Identifiers

PMID41453592
PMCPMC12834116

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.